Articles By Estel Grace Masangkay

  1. NewLink Genetics, Genentech Ink $1 Billion Cancer Drug Deal 10/23/2014

    Biopharmaceutical company NewLink Genetics announced that it has signed into an exclusive global license agreement with Roche’s Genentech to develop NewLink’s IDO pathway inhibitor NLG919 for cancer.

  2. University Begins Ebola Vaccine Trials In Malian Health Workers 10/20/2014

    The Center for Vaccine Development (CVD) at the University of Maryland School of Medicine (UM SOM) announced that it has begun the clinical trial for its investigational Ebola vaccine for healthcare workers in collaboration with its sister institution the Center for Vaccine Development of Mali (CVD-Mali) and the Ministry of Health of Mali.

  3. Sanofi Pasteur Links With Immune Design For HSV Vaccine 10/20/2014

    Sanofi’s vaccine division Sanofi Pasteur announced that it has entered into a collaboration with clinical stage immunotherapy firm Immune Design to develop a vaccine for herpes simplex virus (HSV).

  4. Novartis' Secukinumab Maintains Efficacy In Psoriasis Trial 10/17/2014

    Novartis reported that results from a Phase 3 trial show that AIN457 (secukinumab) successfully maintained efficacy in patients with psoriasis.

  5. Biotron's HCV Drug Clears All Symptoms In Patients 10/17/2014

    Australia-based drug development firm Biotron reported positive results from the Phase 2 trial of its lead antiviral agent BIT225 for the treatment of patients with hepatitis C virus (HCV).

  6. PhRMA Takes Further Action Against HHS' Orphan Drug Rule 10/15/2014

    The Pharmaceutical Research and Manufacturers of America (PhRMA) has filed a second lawsuit challenging the 340B Orphan Drug Rule after the Washington D.C. District Court ruled last month that its original suit did not apply to the interpretive rule implemented by the HHS’ Health Resources and Services Administration (HRSA).

  7. Pfizer Posts Immunogenicity Data For Meningococcal B+HPV4 Vaccine 10/13/2014

    Pfizer will present the results of a Phase 2 study investigating the co-administration of its meningococcal group B vaccine, bivalent recombinant LP2086 (rLP2086), together with a quadrivalent human papillomavirus (HPV4) vaccine, at IDWeek 2014 taking place until this weekend in Philadelphia.

  8. GSK's Stiefel Begins Phase 3 Study For Ofatumumab 10/13/2014

    GlaxoSmithKline announced that its company Stiefel has begun the Phase 3 study of subcutaneous ofatumumab in rare autoimmune skin disorder, pemphigus vulgaris.

  9. NIH: Avian Flu Vaccine Candidate Works Better With Adjuvant 10/10/2014

    The National Institutes of Health (NIH) reported that results from its sponsored trial shows its investigational vaccine against H7N9 avian flu works best when teamed up with an adjuvant.

  10. FDA Fast Tracks BrainStorm Cell's ALS Stem Cell Treatment 10/10/2014

    BrainStorm Cell Therapeutics, an Israel-based biotech firm that develops adult stem cell treatments for neurodegenerative diseases, announced that its NurOwn has been given Fast Track status by the U.S. Food and Drug Administration (FDA) as treatment for amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's Disease.